Clinical Trial Update: Phase I Study of [111In]-FPI-2107 in EGFR Mutation-positive NSCLC [Phase 1]

View source ↗

Summary

A Phase I clinical trial evaluating the radiolabeled compound [111In]-FPI-2107 in patients with EGFR mutation-positive non-small cell lung cancer is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• [111In]-FPI-2107 (Indium-111 labeled FPI-2107)

Snippet

Sponsor: AstraZeneca | Conditions: EGFR Mutation-positive NSCLC | Phase 1 | Status: RECRUITING